The Maximum Tolerated Dose for Inhalation Bioassays: Toxicity vs Overload
نویسندگان
چکیده
منابع مشابه
Liposomal cisplatin dose escalation for determining the maximum tolerated dose and dose-limiting toxicity: a phase I study.
BACKGROUND The aim of the present trial was to determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of liposomal cisplatin (lipoplatin) using nephrotoxicity, gastrointestinal toxicity and myelotoxicity as the main adverse reactions. PATIENTS AND METHODS Lipoplatin, a liposomal formulation of cisplatin was first tested as monotherapy starting at a dose of 125 mg/m(2) and...
متن کاملPulmonary carcinogenicity of inhaled particles and the maximum tolerated dose.
Chronic inhalation bioassays in rodents are used to assess pulmonary carcinogenicity for purposes of hazard identification and potentially for risk characterization. The influence of high experimental doses on tumor development has been recognized for some time and has led to the concept of maximum tolerated dose (MTD) for dose selection, with the highest dose being at the MTD. Exposure at the ...
متن کاملDetermination of maximum tolerated dose and toxicity of Inauhzin in mice
Reactivating the tumor suppressor p53 offers an attractive strategy for developing cancer therapy. We recently identified Inauhzin (INZ) as a novel non-genotoxic p53-activating compound. To develop INZ into a clinically applicable anticancer drug, we have initiated preclinical toxicity studies. Here, we report our study on determining the maximum tolerated dose (MTD) of INZ analog, Inauhzin-C (...
متن کاملThe relationship between carcinogenic potency and maximum tolerated dose is similar for mutagens and nonmutagens.
Correlations between carcinogenic potency (p or I,/TDsa) and acute toxicity (I-D& and between carcinogenic potency and maximum tolerated dose (MTD) have been described by several authors (l-5). The correlations have been attributed in part to a bias inherent in the carcinogenicity bioassay, namely, that the carcinogenic potencies of chemicals that are highly toxic and only weakly carcinogenic c...
متن کاملDose Titration Algorithm Tuning (DTAT) should supersede ‘the’ Maximum Tolerated Dose (MTD) in oncology dose-finding trials
Background. Absent adaptive, individualized dose-finding in early-phase oncology trials, subsequent 'confirmatory' Phase III trials risk suboptimal dosing, with resulting loss of statistical power and reduced probability of technical success for the investigational therapy. While progress has been made toward explicitly adaptive dose-finding and quantitative modeling of dose-response relationsh...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Toxicological Sciences
سال: 1996
ISSN: 1096-6080,1096-0929
DOI: 10.1093/toxsci/29.2.155